NCT03821363Unknown1 期
Recombinant Humanized Anti- PD-1 Monoclonal Antibody（SCT-I10A） in Patients With Advanced Solid Tumors or Lymphoma :a Phase Ⅰ, Open-label, Multicenter Study
适应症
干预措施
试验速览
- 阶段
- 1 期
- 入组人数
- 206
- 试验地点
- 1
- 主要终点
- Safety/Tolerability
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of recombinant humanized anti- PD-1 monoclonal antibody（SCT-I10A）in patients with advanced solid tumors or lymphoma treated after failure of standard therapy.
详细描述
This open label, multicenter phase I study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy in advanced solid tumors or lymphoma treated with anti- PD-1 monoclonal antibody SCT-I10A. The trial will be divided into two parts: dose-exploration and indication expansion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to provide written informed consent before screening；
- •Males or females. Aged 18 to 75 years old;
- •Life expectancy≥12 weeks before starting treatment (clinical assessment);
- •With an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1;
- •Histologically or cytologically confirmed advanced solid tumor or lymphoma;
- •Advanced solid tumor or lymphoma with standard treatment failed or no effective therapy;
- •According to RECIST 1.1 or Lugano 2014 criteria, patients must have at least one measurable lesion that can be accurately assessed;
- •Adequate organ and bone marrow function as defined below:
- •Absolute neutrophil count (ANC) greater than/equal to 1.5×l09/L; Platelets greater than/equal to 75×109/L; Hemoglobin greater than/equal to 80g/L; Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than/equal to 2.5 times ULN, or less than/equal to 5 times ULN if known liver metastases; Total bilirubin less than/equal to 1.5 times ULN; Serum creatinine less than/equal to 1.5 times ULN or Ccr>50ml/min; Thyroid stimulating hormone (TSH) hormone levels less than/equal to ULN.
排除标准
- •Patients who are allergic to analogue of SCT-I10A and/or its inactive ingredients;
- •Patients have been treated with anti-PD-L1 and anti-PD-1 antibody;
- •Patients are currently enrolled in other research devices or in research drugs, or less than 4 weeks from other research drugs or devices;
- •Within 4 weeks prior to the first dose of study drug, patients have received anti-tumor drugs (such as chemotherapy, endocrine therapy, targeted therapy, immune therapy, tumor embolization). Within 6 weeks prior to the first dose of study drug, patients have been treated with biological products, nitrosourea or mitomycin C;
- •Within 2 weeks prior to the first dose of study drug, patients have received corticosteroids or other immunosuppressive agents;
- •Within 4 weeks prior to the first dose of study drug, patients have received live attenuated vaccine (LAV), or who planned to use LAV during the study period;
- •Within 4 weeks prior to the first dose of study drug, patients have received major surgery, or had wounds, ulcers or fractures that haven't healed;
- •Prior to the first dose of study drug, patients had toxicity due to previous anti-tumor treatment, which hasn't return to Grade 0-1 according to the NCI CTCAEv4.03;
- •Patient with cerebrospinal meningitis metastasis or central nervous system metastasis with untreated or uncontrolled with other treatment;
- •Patients with an active, known or suspected autoimmune disease or a history of autoimmune disease;
- •Patients with a history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
- •Within 6 months prior to study, patients had uncontrolled concurrent diseases, including but not limited to acute myocardial infarction, unstable angina pectoris, stroke, or transient ischemic attack, congestive heart failure (NYHA, greater than II), left ventricular ejection fraction (LVEF) <50%, and with related heart disease. Patients with chronic or acute disease, psychological or psychiatric disorders, laboratory abnormalities which may affect subject compliance and outcomes in this clinical study;
- •Patients with HIV, active hepatitis B (HBV DNA≥104 copies/ml) or active hepatitis C (HCV RNA≥103 copies/ml), etc.;
- •Patients who have interstitial lung disease, such as interstitial pneumonia, pulmonary fibrosis, or CT or MRI reminder ILD.
- •Patients with clinical symptoms, required clinical intervention or stable time less than 4 weeks of serous cavity effusion (such as pleural effusion and ascites);
- •Patients with other primary malignancies;
- •Pregnant or lactating women;
- •Patients who were not willing to accept effective contraceptive measures during treatment and within 6 months after treatment;
- •Subjects who are considered not suitable for the study by investigator.
研究组 & 干预措施
Middle dose group
Experimental
SCT-I10A will be administered at a dose of 200mg, Q3W up to 24 months.
干预措施: SCT-I10A (Biological)
Low dose group
Experimental
SCT-I10A will be administered at a dose of 60mg, Q3W up to 24 months.
干预措施: SCT-I10A (Biological)
High dose group
Experimental
SCT-I10A will be administered at a dose of 600mg, Q3W up to 24 months.
干预措施: SCT-I10A (Biological)
结局指标
主要结局
Safety/Tolerability
时间窗: 24 months
Incidence of adverse events and outlier of laboratory tests, positive rate of immunogenicity
次要结局
- Disease control rate (DCR)(24 months)
- Progression free survival (PFS)(24 months)
- Objective response rate (ORR)(24 months)
- Duration of response (DOR)(24 months)
- Overall survival (OS)(24 months)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520Advanced Solid Tumor，Recurrent Solid Tumor，Lymphoma，Recurrent Lymphocyte Depleted Classical Hodgkin LymphomaNCT03657381Shandong New Time Pharmaceutical Co., LTD75
Unknown
3 期
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung CancerIIIB/IIIC/IV Lung CancerNCT03944980Tianjin Medical University Cancer Institute and Hospital146
招募中
3 期
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal CancerColorectal CancerNCT03950154Tianjin Medical University Cancer Institute and Hospital198
已完成
1 期
Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin's LymphomaLymphomaNCT00004101National Cancer Institute (NCI)35
已完成
1 期
An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant TumorAdvanced Malignant TumorNCT04739111Dragonboat Biopharmaceutical Company Limited12